Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection.
OPEN FORUM INFECTIOUS DISEASES(2018)
摘要
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.
更多查看译文
关键词
chronic lymphocytic leukemia,ibrutinib,Mycobacterium chelonae,nontuberculous mycobacteria,skin and soft tissue infection
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要